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Depressive symptoms are common in schizophrenia, often 
left untreated, and associated with a high relapse rate, sui-
cidal ideation, increased mortality, reduced social adjust-
ment and poor quality of life. The neural mechanisms 
underlying depression in psychosis are poorly understood. 
Given reports of altered brain response to negative facial 
affect in depressive disorders, we examined brain response 
to emotive facial expressions in relation to levels of depres-
sion in people with psychosis. Seventy outpatients (final 
N = 63) and 20 healthy participants underwent functional 
magnetic resonance imaging during an implicit affect pro-
cessing task involving presentation of facial expressions 
of fear, anger, happiness as well as neutral expressions 
and a (no face) control condition. All patients completed 
Beck Depression Inventory (BDI-II) and had their symp-
toms assessed on the Positive and Negative Syndrome 
Scale (PANSS). In patients, depression (BDI-II) scores 
associated positively with activation of the left thalamus, 
extending to the putamen-globus pallidus, insula, infe-
rior-middle frontal and para-post-pre-central gyri during 
fearful expressions. Furthermore, patients with moderate-
to-severe depression had significantly higher activity in 
these brain regions during fearful expressions relative to 
patients with no, minimal, or mild depression and healthy 
participants. The study provides first evidence of enhanced 
brain response to fearful facial expressions, which sig-
nal an uncertain source of threat in the environment, in 
patients with psychosis and a high level of self-reported 
depression.
Key words: psychosis/depressive symptoms/ 
fMRI/fear/thalamus
Introduction
Depression has been regarded as a key feature of schizo-
phrenia since it was first defined by Bleuler.1 A large body 
of evidence confirms that depressive symptoms are a core 
component,2,3 and may precede the clinical manifesta-
tion4,5 of psychosis. Prevalence rates for major depres-
sive disorder (MDD) comorbid with psychotic disorders 
commonly vary between 25% to 75%,6,7 and around 70% 
of chronic schizophrenia patients without a MDD may 
show signs of sub-syndromal depression.2,3 Although 
there is overlap between depressive and negative symp-
toms, a distinction between them can be made,8,9 with 
negative symptoms indicating the severity of illness and 
depressive symptoms reflecting motivational hopeless-
ness about the future.8 Importantly, depressed mood 
in schizophrenia is known to have detrimental conse-
quences, such as a high relapse rate, suicidal ideation, 
increased mortality, reduced social adjustment and poor 
quality of life.8,10–14 A key question, central to refining and 
developing effective treatments for depression in schizo-
phrenia is: what are the psychobiological abnormalities 
associated with depressive symptoms in schizophrenia, 
and to what extent are they similar or different to those 
commonly observed in MDD?
A large number of functional magnetic resonance imag-
ing (fMRI) studies have already examined the neurobiol-
ogy of MDD, particularly using facial affect processing 
paradigms.15 MDD patients, relative to healthy partici-
pants, show hyper-activation to negative facial affect, in 
particular sadness and fear, in the amygdala, insula, para-
hippocampal gyrus, fusiform face area and putamen.16–19 
Structural and functional alterations in these regions are 
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widely implicated in disturbed implicit/explicit processing 
of emotive stimuli and poor affect regulation in MDD.20–
22 Schizophrenia patients, on the other hand, are reported 
to show, on average, reduced activation of the amygdala, 
parahippocampal gyrus, superior frontal gyrus, insula 
and basal ganglia to negative facial affect.23,24 There are 
no fMRI studies to our knowledge specifically examining 
the role of depression in brain responses to negative facial 
affect in schizophrenia. Amygdala activation to fearful 
faces, however, was found to correlate positively with the 
severity of flat affect, a negative symptom dimension, in 
a previous study.25
There is indirect support from structural brain imag-
ing and neuropsychological studies that depressed mood 
in schizophrenia and MDD could have at least partially 
overlapping neurobiology, such as volumetric abnormali-
ties of the temporal lobe and anterior cingulate26 and 
attentional impairment.27 Depression in schizophrenia, 
however, differs markedly amongst patients depending 
on the stage of the illness, with more severe depressive 
symptoms in first episode patients, perhaps as a natural 
reaction to developing psychotic symptoms, relative to 
multi-episode chronic patients.28,29 Depression in later 
phases of the illness is found to be more subjective and 
best detected with self-report instruments,29,30 such as the 
Beck Depression Inventory.31
In this study, our aim was to elucidate the neural cor-
relates of subjective depression, using whole brain fMRI 
during an established facial affect paradigm,32 in patients 
with schizophrenia or schizoaffective disorder. Assuming 
depression in chronic psychosis patients to share func-
tional brain abnormalities associated with MDD,15–17 we 
expected to find a positive association between the level 
of self-reported depression and brain activity, particu-
larly in the amygdala, insula, parahippocampal gyrus, 
fusiform face area and putamen, during negative facial 
affect processing. In addition, we studied a group of 
healthy participants to examine whether a positive associ-
ation between depression and brain activity in patients, if  
found, reflected a hyperresponse, or a stronger response 
within the normal range, in patients with moderate-to-
severe depression.
Methods and Materials
Participants and Design
The study involved 70 right-handed33 outpatients with 
a DSM-IV diagnosis34 of schizophrenia or schizoaf-
fective disorder, recruited from the South London and 
Maudsley NHS Foundation Trust (SLaM), United 
Kingdom. Twenty right-handed33 healthy participants 
(with no current or previous diagnosis of an Axis I disor-
der35) matched, on average, to age and sex of the patient 
group were also studied.
All recruited patients met the following inclusion 
criteria: (1) aged 18–65 years, (2) on a stable dosage of 
antipsychotic medication for at least 3 months prior to 
taking part, (3) no history of neurological impairments, 
systematic illness or head injury, (4) no current substance 
use disorder, and (5) able to provide written informed 
consent. The final study sample consisted of 63 patients 
(table 1), out of 70 recruited initially, for whom we had 
obtained usable fMRI data, symptom ratings using the 
Positive and Negative Syndrome Scale (PANSS)36 and 
who had fully completed (within 1 wk of fMRI) the Beck 
Depression Inventory-II (BDI-II).31 PANSS assessments 
on patients were carried out by an experienced psychia-
trist (D.F.) who was blind to patients’ BDI-II scores.
The study procedures were approved by the ethics com-
mittee of the joint research ethics committee of the SLaM 
and the Institute of Psychiatry, London. All participants 
provided written informed consent prior to their partici-
pation and were compensated for their time and travel.
fMRI Paradigm and Procedure
The task involved presentation of black and white pic-
tures of faces from Ekman and Friesen’s set.37 Three types 
of emotions (fear, anger, happy; 100% expression) and 
relatively neutral expressions were displayed in 30-second 
blocks of 8 pictures each, with each picture presented for 
3.75 seconds. There were sixteen 30-second blocks with 
facial expressions (4 fear, 4 anger, 4 neutral, 4 happy), and 
each block was followed by a 15-second control block 
during which just an oval frame, as on facial expres-
sion trials and matched for luminance but without the 
face inside, appeared 4 times (order of presentation over 
the 12-minute experiment: neutral-control-fear-control-
happy-control-anger-control-fear-control-anger-control-
neutral-control-happy-control-anger-control-happy-
control-fear-control-neutral-control-happy-control-neu-
tral-control-anger-control-fear-control). The oval frame, 
rather than neutral expressions, was used as the control 
condition because it has been observed that people with 
schizophrenia38,39 or those at a high risk for psychosis40 
may activate brain regions to neutral faces that are nor-
mally associated with fear processing. On presentation 
of each facial expression, participants were required to 
indicate whether the face was a male/female by pressing 
the left (female)/right (male) button on a button box, sim-
ply to ensure they were attending to the stimuli. During 
the no face (oval frame) condition, attention was moni-
tored by asking participants to press either button (left/
right) when the blank oval frame appeared. All partici-
pants underwent task familiarization in advance of the 
scan through practice of the gender discrimination task 
once on all identities used in the fMRI experiment on a 
laptop computer and an identical button box device. The 
task and administration procedures were identical to that 
used in a previous study.32 Participants were requested to 
abstain from alcohol for at least 24 hours prior to their 
scanning. They were provided with tea and decaffeinated 
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coffee, as requested, up until 40 minutes before fMRI. 
Smokers were allowed to smoke as usual to avoid a state 
of smoking/nicotine withdrawal but care was taken not 
to start fMRI scanning them within 40 minutes of smok-
ing a cigarette.
Image Acquisition
Echoplanar MR brain images were acquired using a 
1.5 T GE Signa system (General Electric). In each of 16 
near-axial noncontiguous planes parallel to the inter-
commissural plane, 240 T2*-weighted MR images depict-
ing blood-oxygen-level-dependent (BOLD) contrast 
(echo time [TE] 40 ms, repetition time [TR] 3 s, Flip 90°, 
field of view 240 mm, matrix 64 × 64, in-plane resolution 
3.1 mm, slice thickness 7.0 mm, interslice gap 0.7 mm) 
were acquired over the 12-minute experiment. In the 
same session, a high resolution 3-D inversion recovery 
prepared spoiled GRASS volume dataset was acquired 
with TE = 5.3 ms, TI = 300 ms, TR = 12.2 ms, in-plane 
resolution = 0.94 mm, slice thickness = 1.5 mm.
Data Analysis
All behavioral analyses were performed using Statistical 
Package for Social Sciences (version 22). Alpha level for 
testing significance of effects was maintained at P < .05 
unless stated otherwise.
Demographic, Behavioral and Clinical Measures. Patients 
and healthy participants were compared on age, educa-
tion, predicted IQ41 and BDI-II scores using independent 
sample t tests. Patient subgroups with varying depression 
levels (no/minimal: BDI-II score 0–13; mild: score 14–19, 
moderate-to-severe: score 20 or above) were compared 
on age, education, predicted IQ41 and PANSS symptoms 
using (separate) 1-way ANOVA, with Depression (no/
minimal, mild, moderate-to-severe) as a between-subjects 
factor, followed by independent sample t tests where 
needed.
Group and emotion effects in performance accuracy 
(%  correct gender discrimination in facial expressions) 
and latency (reaction time to correct responses) were 
analysed separately using a Group (patients, healthy par-
ticipants) × Emotion type (fear, anger, neutral, happy) 
repeated-measures ANOVA with Group as the between-
subjects factor and Emotion type as the within-subjects 
factor, followed by post hoc mean comparisons. The 
effects of varying depression in performance accuracy 
and latency of patients were analyzed (separately) using 
Depression × Emotion type ANOVA with Depression 
as the between-subjects factor and Emotion type as the 
within-subjects factor, followed by lower order ANOVAs 
and post hoc mean comparisons. Finally, Pearson’s cor-
relations were used to examine relationship of BDI-II 
scores to performance (accuracy and latency), symptoms, 
age, illness duration and the doses of antipsychotic medi-
cation in the patient group.
fMRI
Preprocessing. For each participant, the 240 volume 
functional time series were realigned to the first vol-
ume, corrected for motion artefacts (x, y and z transla-
tion, pitch, roll, yaw; time series with translations >5 
mm or rotations > 5° were excluded from the analysis), 
transformed into stereotactic space using the EPI tem-
plate in SPM (affine transformation x, y and z, 16 non-
linear iterations, 7 × 9  × 7 basis functions), spatially 
smoothed with a 10 mm FWHM Gaussian filter and 
band pass filtered using statistical parametric mapping 
software (SPM5; http://www.fil.ion.ucl.ac.uk/spm).
Models and Statistical Inferences. Data were analyzed 
using a random effect procedure.42 Participant-specific acti-
vations were identified with a factorial model consisting of 
4 facial expression conditions, and no face control condi-
tion serving as an implicit baseline. The boxcar for each 
30-second epoch was convolved with the haemodynamic 
response function. Motion parameters were included as 
covariates at this stage. The second stage of the random 
effect model identified generic task-related activations in 
the patient and healthy groups (separately) for each facial 
expression condition (fear, anger, neutral, happy) vs no 
face control condition (height threshold P < .005; cluster-
corrected P ≤ .05), using statistical parametric mapping 
software (SPM8; http://www.fil.ion.ucl.ac.uk/spm).
The relationship of BDI-II scores in patients with neural 
activity across the whole brain was first examined (height 
threshold P < .05; cluster-corrected P ≤ .05), using regres-
sion model within SPM8 with BDI-II scores entered as a 
covariate for each facial expression condition (fear, anger, 
neutral, happy) vs no face control condition; and also for 
each emotional expression (fear, anger, happy) vs the neu-
tral expression following the observation of no relationship 
between BDI-II scores and activity to neutral expressions 
(see Results). In addition, all regression analyses were 
repeated with gender included as an additional covariate. 
Since the inclusion of gender revealed the same cluster 
associations, the results of these additional SPM regres-
sions are not reported hereafter. The participant-specific 
activation values were then extracted from the clusters 
(peak voxel) that showed a relationship with BDI-II scores 
in the patient group, and examined (within the SPSS) for 
their possible relationships with symptoms, age, illness 
duration and the doses of antipsychotic medication (in 
chlorpromazine equivalents) using Pearson correlations.
Next, we extracted participant-specific mean BOLD 
signal for all patients and healthy participants from 
each of  2 activation clusters (thalamus and superior 
frontal gyrus [SFG]; 10 mm sphere around the peak 
voxel) that showed a significant association with 
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BDI-II scores during fearful expression in SPM regres-
sion analyses (table  2) using the MarsBaR toolbox 
(http://marsbar.sourceforge.net/projects/marsbar). 
These data were then analysed (within the SPSS) to 
confirm the influence of  depression in patients’ brain 
activity using a Region (thalamus, SFG) × Emotion 
type (fear, anger, happy, neutral) × Depression (no/
minimal, mild, moderate-to-severe) ANOVA, followed 
by lower order ANOVAs and mean comparisons as 
needed. A  further Region (thalamus, SFG) × Group 
(healthy participants, no/minimal depression patients, 
mild depression patients, moderate-to-severe depres-
sion patients) ANOVA was conducted to establish 
whether higher activations during fearful expressions 
in patients with moderate-to-high depression, relative 
to those with no/minimal/mild depression (detected 
with the earlier ANOVA), reflected a hyperresponse or 
a stronger response within the normal range.
Table 2. Significant Associations Between Brain Activity to Fearful Expressions and Depression in Patients (Voxel Threshold P < .005 
Uncorrected)
Fearful > No Face Control
Brain Area BA Voxels (n) Side
MNI Coordinates
Voxel T Cluster-Corrected Px y z
Ventral posterior medial nucleus (thalamus) 5422 Left −16 −22 0 4.31 .018
Postcentral gyrus 3 Left −50 −14 48 3.17
Globus pallidus (lentiform nucleus) Right 18 −12 −4 3.10
Supramarginal gyrus 40 Left −32 −50 32 3.06
Insula Left −36 −48 24 3.01
Inferior frontal gyrus 9 Left −48 6 28 2.95
Postcentral gyrus 3 Left −48 −20 48 2.93
Precentral gyrus 4 Left −32 −20 52 2.91
Paracentral lobule 5 Left −14 −44 62 2.89
Postcentral gyrus 2 Left −48 −24 52 2.86
Supramarginal gyrus 40 Left −36 −48 30 2.84
Postcentral gyrus 2 Left −48 −24 46 2.73
Superior parietal lobule 7 Left −34 −52 50 2.73
Fearful > Neutral
Superior frontal gyrus 6 9081 Right 4 10 60 4.49 <.001
6 Right 4 16 58 4.11
Medial frontal gyrus 6 Right 14 −4 60 3.94
6 Right 12 0 60 3.91
Middle frontal gyrus 6 Right 42 −4 46 3.51
Superior frontal gyrus 6 Right 8 22 56 3.50
Precentral gyrus 6 Left −38 −10 58 3.28
Medial frontal gyrus 6 Left −12 2 62 3.26
Middle frontal gyrus 6 Left −20 −20 62 3.24
Precentral gyrus 4 Left −32 −20 52 3.24
6 Right 50 2 46 3.23
Precentral gyrus 6 Left −24 −22 62 3.17
Superior frontal gyrus 8 Right 10 26 54 3.15
Precentral gyrus 4 Left −50 −10 46 3.08
Anterior cingulate 24 Left −12 0 52 3.08
Ventral posterior medial nucleus (thalamus) 3805 Left −18 −22 2 3.74 .009*
Insula Left −40 −12 10 3.30
Hippocampus Right 30 −22 −8 2.78
Mammillary body (thalamus) Right 10 −18 −2 2.72
Thalamus Right 10 −16 4 2.70
Putamen (lentiform nucleus) Right 28 −18 8 2.69
Transverse temporal gyrus 41 Left −52 −16 8 2.68
Putamen (lentiform nucleus) Right 30 −18 4 2.67
Claustrum Right 34 −22 2 2.64
Ventral lateral nucleus (thalamus) Right 20 −16 8 2.43
Globus pallidus (lentiform nucleus) Right 20 −12 0 2.35
Caudate Right 10 4 8 2.30
Note: BA, Brodmann area; MNI, Montreal Neurological Institute.
*Uncorrected P.
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Results
Demographic, Behavioral and Clinical Measures
Patients and healthy participants were comparable 
(table  1) on age, sex distribution and education (P val-
ues > .18) but patients had significantly lower premorbid 
IQ (t79 = 3.21, P = .002). Patients also rated themselves 
much higher on BDI-II depression (t81 = 5.46, P < .001). 
Patients with varying levels of depression (table  1) did 
not differ in age, sex distribution, education, age at illness 
onset, illness duration, antipsychotic dose, and PANSS 
positive, negative or total symptoms (P values > .16) but 
differed marginally in general psychopathology scores 
(F2,60 = 1.90, P = .05). The no/minimal depression sub-
group, relative to the mild (F1,44 = 4.79, P = .03) and mod-
erate-to-severe (F1,40 = 4.12, P = .05) depression subgroups 
had lower general psychopathology scores (accounted for 
by the positive correlation, described below, between the 
BDI-II and general psychopathology scores).
Both healthy and patient groups showed a high level 
of gender discrimination accuracy across all conditions 
(table 1). This was expected given the easy task demands, 
implemented simply to ensure patients’ attention to task 
stimuli and not place cognitive demands on them. For 
accuracy, there was a significant main effect of Emotion 
type (F3,243 = 5.84, P < .001) but there was no effect of 
Group (F1,81  =  1.30, P  =  .26) or a Group × Emotion 
type interaction (F3,243 = 1.15, P = .33). The main effect 
of Emotion type indicated a lower accuracy for angry 
expressions than for fearful (t82 = 2.36, P = .02), neutral 
(t82 = 3.21, P = .002) and happy expressions (t82 = 6.32, P 
< .001), and in addition, for fearful (t82 = 0.89, P = .005) 
and neutral (t82  =  5.33, P < .001), relative to happy 
expressions. There was no significant difference between 
fearful and neutral expressions (t82 = 0.09, P = .93). For 
latency, no significant effects were found (Emotion type: 
F3,243 = 1.58 P = .19; Group: F1,81 = 2.83, P = .10; Emotion 
type × Group: F3,243 = 1.23, P = .30).
Patient subgroups with varying depression levels 
also showed comparable accuracy across all condi-
tions (table  1), with no significant effect of Depression 
(F2,60 = 1.42, P =  .25). There was a significant effect of 
Emotion type (F3,180 = 9.14, P < .001; reflecting the same 
pattern as above) but no Depression × Emotion type 
interaction (F6,180 = 0.56, P = .76). There was no effect of 
Depression (F2,60 = 1.38, P = .26), or any other effect, in 
latency.
In patients, BDI-II (depression) scores had modestly 
positive correlation with PANSS general psychopathol-
ogy (r = .309, P = .014; for PANSS-G6 depression item, 
ρ =  .353, P < .01) but had no correlation with PANSS 
positive (r = .01) or negative symptoms (r = .11). BDI-II 
scores did not correlate with accuracy or latency during 
any task condition (all P > .10), age (r = .02, P = .94), ill-
ness duration (r = .006, P = .96) or doses of antipsychotic 
medication (r = .004, P = .98).
fMRI
Generic Task Related Activations in Patients and Healthy 
Participants. The areas showing significant activity 
changes for each facial expression condition vs no face 
control condition in patient and healthy groups are 
described in supplementary appendix 1, and displayed 
in figure  1 (the clusters which did not reach corrected 
cluster-level significance are also displayed in figure 1 for 
completeness).
In patients, robust activation for fearful expressions 
(>no face) was limited to the right inferior frontal gyrus, 
with weaker (uncorrected; displayed in figure 1) activity 
seen in the left inferior frontal gyrus (peak, x  =  −40, 
y = 8, z = 32, cluster size = 417 voxels), right striatum-
hippocampus-parahippocampal gyrus (x = 30, y = −6, 
z  =  −10; 401 voxels), and the left precentral gyrus 
(x = 36, y = −20, z = 62; 417 voxels; figure 1). Significant 
activations for angry expressions included the inferior 
frontal gyrus (bilateral), thalamus (bilateral), para-
hippocampal gyrus (right), globus pallidus (left) and 
middle occipital gyrus (right). For neutral expressions, 
robust activation was seen in the middle frontal gyrus 
(bilateral), precentral gyrus (left), thalamus (bilateral) 
and globus pallidus (left); in addition, there was weak 
(uncorrected level) activation of  the left superior pari-
etal cortex (x  =  30, y  =  −60, z  =  52; 721 voxels; fig-
ure  1). No area was activated for happy expressions 
at the corrected level but 2 clusters with uncorrected 
significance were present, 1 in the right inferior-middle 
frontal gyrus (x = 42, y = 10, z = 24; 447 voxels) and 
the other in the left precentral gyrus (x = −32, y = −22, 
z = 62; 461 voxels; figure 1).
In healthy participants, fearful expressions activated 
parts of  the inferior occipital gyrus, inferior-middle 
frontal gyri, striatum, insula, amygdala, hippocam-
pus, parahippocampal gyrus and the thalamus. Angry 
expressions mainly activated the inferior occipital gyrus, 
cuneus and the inferior-middle frontal gyrus. Neutral 
expressions activated the inferior occipital and fusiform 
gyri, cuneus, insula and the caudate. Happy expressions 
activated only the inferior-middle occipital and fusi-
form gyri and the cuneus (supplementary appendix 1; 
figure 1). In general, the magnitude of  activations across 
all conditions in healthy participants was greater than in 
patients.
Depression and Brain Activity in Patients. Regression 
Analyses Depression (BDI-II) scores correlated signifi-
cantly positively with activity during fearful expressions 
(>no face) in the left thalamus extending to the para-
post-pre-central gyrus, putamen-globus pallidus, supra-
marginal gyrus, insula and inferior-middle frontal gyrus 
(table 2, figure 2). BDI-II scores also correlated signifi-
cantly positively with activity for fearful expressions when 
compared with neutral (fearful > neutral) expressions 
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in the right SFG extending to middle/medial frontal, 
left precentral and left anterior cingulate gyri. Another 
cluster, very similar to the cluster found to correlate pos-
itively with BDI-II scores during fearful > nonface con-
trast, with near identical peak in the left thalamus, was 
also present at uncorrected significance (table 2, figure 2). 
BDI-II scores did not correlate significantly (positively or 
negatively) with activation of any area during angry, neu-
tral or happy expressions.
Participant-specific activation values extracted from 
peak voxel of the above 3 clusters that associated posi-
tively with BDI-II scores (peak of cluster 1 in the thala-
mus, fearful > no face control contrast; of cluster 2 in the 
superior frontal gyrus, and of cluster 3 in the thalamus, 
both fearful > neutral face contrast) did not correlate 
significantly with PANSS total or subscale scores (all r 
values <.17). Participant-specific activation values associ-
ated positively with BDI-II scores also did not correlate 
with age (r values −.009 to .045; all P > .72), duration 
of illness (r values −.015 to .03; all P > .80) or anti-
psychotic medication dose (r values −.039 to −.025; all 
P > .76), and their correlation with BDI-II scores 
remained significant with near identical P values (all P ≤ 
.001) after controlling (partial r) for age, illness duration 
or doses of antipsychotic medication.
Categorical Analyses The Region × Emotion type × 
Depression (2 × 4  × 3)  ANOVA to examine differences 
between patient subgroups revealed a significant Region × 
Emotion type effect (F3,180 = 2.82, P = .04) and a trend for 
Emotion type × Depression effect (F6,180 = 1.76, P = .11) 
with a significant linear trend (F2,603  =  3.81, P  =  .026). 
Follow-up analyses of these effects using Region × 
Depression ANOVAs separately for fearful, angry, happy 
and neutral expressions revealed a significant Depression 
effect for fearful expressions (F2,60 = 4.86, P = .01). This 
effect was due to significantly higher activity across the 
thalamic and SFG clusters in moderate-to-severe depres-
sion subgroup, relative to no/minimal (F1,44  =  8.97, 
P = .004) and mild depression (F1,36 = 5.32, P = .03) sub-
groups; no/minimal and mild depression subgroups did 
not differ from each other (F1,40 = 0.04, P = .85; figure 3). 
Region × Depression ANOVAs (separately) for angry, 
Fig. 1. Task related increases (facial expressions > no face control stimuli) in patient and healthy groups with associated Montreal 
Neurological Institute (MNI) x, y and z coordinates (maps thresholded at P = .005 uncorrected). For each coordinate, sagittal and axial 
slices are shown. The left hemisphere is shown at the top of the axial slices.
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happy and neutral expressions did not reveal any signifi-
cant effects (figure 3).
Further Region × Group (no/minimal depression, mild 
depression and moderate-to-severe depression patients, 
and healthy participants) ANOVA to specifically probe 
activity differences for fearful expressions in moderate-
to-severe depression patients, relative to healthy partici-
pants, also revealed a significant Group effect (F3,79 = 3.88, 
P = .01). This effect was due to significantly higher activ-
ity in the moderate-to-severe depression patient sub-
group, relative to the healthy group (F1,39 = 5.89, P = .02) 
and no/minimal and mild depression patient subgroups 
(effects already described). Patients with no/minimal 
(F1,43  =  0.36, P  =  .55) or mild depression (F1,35  =  0.34, 
P = .56) did not differ from healthy participants (or each 
other, as described earlier).
Discussion
Our primary aim was to determine the brain activity asso-
ciated with depression, as indexed with BDI-II, in patients 
with chronic schizophrenia during implicit processing of 
facial affect. The findings partially confirmed our a priori 
hypothesis in that there was a significantly positive asso-
ciation between depression (BDI-II) scores and brain 
activity to facial expressions of fear. This association was 
Fig. 2. Brain activity positively associated with Beck Depression Inventory (BDI-II) depression with associated Montreal Neurological 
Institute (MNI) x, y and z coordinates (maps thresholded at P = .05 uncorrected; displayed clusters significant at corrected P ≤ .05). For 
each coordinate, sagittal and axial slices are shown. The left hemisphere is shown at the top of the axial slices.
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robustly present (fearful > no face control) in a cluster 
that peaked in the left thalamus and extended to include 
parts of the insula, globus pallidus, and inferior-middle 
frontal and pre-post-para-precentral gyri. Although the 
thalamic cluster was present at the uncorrected level in 
fearful > neutral expressions contrast, it was in the same 
location as detected with fear > no face control contrast, 
and extended to include parts of the caudate, putamen, 
insula and hippocampus. In addition, during fearful > 
neutral contrast, bilateral activity in the superior-middle-
medial frontal gyrus, extending to the precentral gyrus 
and anterior cingulate, was associated significantly posi-
tively with BDI-II scores. Importantly, patients with 
moderate-to-severe depression had significantly greater 
brain activity in these regions during fearful expressions, 
relative to patients with no/minimal/mild depression and 
healthy participants.
In general, our fMRI observations fit with previous 
findings of enhanced brain activity seen in MDD patients 
in response to facial expressions of fear.15,43 However, 
unlike previous findings in MDD which often show a 
hyperactive amygdala response to fearful expressions,16–18 
we did not find amygdala activation to associate with 
depression in psychosis patients, more likely because of 
their long-term antipsychotic use44–46 or other diagnosis-
related issues,24,43 rather than amygdala response habitu-
ation with repeated exposure to facial stimuli during the 
practice and fMRI sessions,47 since there was amygdala 
activation to fearful expressions in healthy participants 
(figure  1) with identical task and scanning parameters. 
Patients with moderate-to-severe depression in this study 
also showed the strongest activity in the regions that 
showed “fear expressions-depression relationship” but 
were not significantly different from patients with no/
minimum/mild depression or healthy participants dur-
ing angry expressions. Importantly, Gur and colleagues25 
also reported enhanced brain response to fearful, but not 
angry, expressions to be significantly associated with a 
high severity of flat affect in schizophrenia (n = 16) and 
this association was present in the thalamus and hippo-
campus in addition to the amygdala. It is also relevant 
in this context that we32 previously found a more robust 
reduction, following cognitive behavior therapy for psy-
chosis (CBTp), in activity of the inferior frontal, insula, 
thalamus and putamen areas during fearful, than dur-
ing angry, expressions; and improvements in subjective 
Fig. 3. Mean functional magnetic resonance imaging (fMRI) response in the thalamic and superior frontal gyrus clusters (correlated 
with Beck Depression Inventory [BDI-II] scores during fearful, but not other, expressions) in patients with varying depression levels and 
healthy participants (*indicates P < .05; higher than all other groups).
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depression are a consistent and important outcome of 
CBTp.48,49 Taken together, these finding indicate a con-
sistent relationship between depression and altered neu-
ral response to fearful expressions, a signal of uncertain 
threat,50 in schizophrenia. Interestingly, there is recent 
meta-analytic evidence that schizophrenia patients (as a 
group) show under-activation in the entire facial emotion 
processing network whereas those with bipolar disorder 
(BD) show greater thalamic engagement during facial 
emotion processing.24 The present findings regarding 
depression in the context of psychosis, therefore, seem 
related to emotion processing abnormalities in BD, and 
may point towards the use of therapies known to be 
effective for treating depressed mood in BD for treating 
depression in schizophrenia.
Of the regions that showed a positive association with 
depression during the viewing of fearful facial expres-
sions, the pulvinar thalamus, with projections to the 
amygdala,51 has been strongly implicated in the control 
of visual attention,52–54 specifically during rapid detection 
of threatening stimuli.55,56 A negative correlation between 
avoidance response to threatening stimuli and activa-
tion of the pulvinar thalamus, insula and striatum has 
also been previously demonstrated in healthy humans.57 
It is thus possible that patients with mild/severe depres-
sion attended fearful expressions to a greater extent and 
possibly engaged in explicit processing of threat-related 
information.58
The strengths of this study include the use of a large 
sample to examine depression-facial affect processing 
relationship, ie, sufficient power to investigate the ques-
tions of interest. The main limitation of this study is that 
it is cross-sectional in nature and therefore there is no 
direct evidence of cause and effect. Further limitations 
include a lack of reliable information on the proportion 
of patients who met DSM criteria for current/past MDD 
and possible confounding effects of different types and 
dosages of medications. It would be valuable in future 
to conduct longitudinal investigations while monitor-
ing depression and medications, and to directly compare 
patients with schizophrenia and varying levels of depres-
sion to MDD and BD patients with varying levels of 
psychotic symptoms in their responses to facial affect, 
relative to an appropriate baseline (eg, scrambled face)59 
within the same study.
In conclusion, this study provides the first evidence 
that psychosis patients with a high level of subjective 
depression show enhanced brain response to fearful facial 
expressions, particularly in the thalamus. Our findings 
suggest an overlap between schizophrenia patients with 
moderate-to-severe depression and BD patients, the latter 
of which reliably show greater thalamic involvement dur-
ing facial affect processing. Unlike previous findings in 
MDD,16–18 we found no evidence of amygdala activation 
during fearful expression to associate with depression in 
the context of psychosis.
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Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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